Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 9, 2023

Primary Completion Date

August 25, 2023

Study Completion Date

August 25, 2023

Conditions
Hemophilia
Interventions
DRUG

STSP-0601 for Injection

Intravenous Injection

Trial Locations (12)

210000

Nanjing Gulou Hospital, Nanjing

300020

Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin

330038

The First Affiliated Hospital of Nanchang University, Nanchang

400000

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

410000

Xiangya Hospital of Central South University, Changsha

450000

Henan Cancer Hospital, Zhengzhou

473000

The First Affiliated Hospital of Nanyang Medical College, Nanyang

511285

Shenzhen Second People's Hospital, Shenzhen

650000

The Second Affiliated Hospital of Kunming Medical University, Kunming

710000

Xi'an Central Hospital, Xi’an

730000

Lanzhou University First Hospita, Lanzhou

063000

North China University of Technology Affiliated Hospital, Tangshan

All Listed Sponsors
collaborator

Beijing Novikang Medical Technology Co., LTD

UNKNOWN

lead

Staidson (Beijing) Biopharmaceuticals Co., Ltd

INDUSTRY